Wall Street analyst estimates for Hoth Therapeutics, Inc. (HOTH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-09-02 | $-0.14 | ||
| 2026-05-15 | $-0.17 | $-0.14 | -23.4% |
| 2026-03-27 | $-0.16 | $-0.10 | -55.2% |
| 2025-11-12 | $-0.30 | $-0.30 | +0.0% |
| 2025-08-12 | $-0.17 | $-0.27 | +37.0% |
| 2025-05-12 | $-0.27 | $-0.34 | +20.6% |
| 2025-03-28 | $-0.32 | $-0.39 | +17.9% |
| 2024-11-12 | $-0.31 | $-0.30 | -3.3% |
Valuation Ratios
| Price / Book | 2.22 |
| EV / EBITDA | -0.60 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $188 | $28252 | $31622 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$188 | -$28252 | -$31622 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $586843 | $1.0M | $2.1M | $2.9M | $7.5M | $4.9M | $3.5M | $3.2M | $5.9M |
| Selling, General & Admin | $1.3M | $1.2M | $5.1M | $4.4M | $6.6M | $6.1M | $4.2M | $5.0M | $6.4M |
| Operating Expenses | $1.9M | $2.5M | $7.7M | $7.3M | $14.1M | $11.1M | $7.7M | $8.2M | $11.1M |
| Operating Income | -$1.9M | -$2.5M | -$7.7M | -$7.3M | -$14.1M | -$11.1M | -$7.7M | -$8.2M | -$11.1M |
| EBITDA | -$2.0M | -$2.5M | -$7.7M | -$7.3M | -$14.3M | -$990 | -$153149 | $27132 | -$12.5M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | $305409 | 0 | 0 | 0 |
| Pre-tax Income | -$2.0M | -$2.5M | -$7.7M | -$7.2M | -$14.3M | -$11.4M | -$7.8M | -$8.2M | -$12.5M |
| Income Tax | $2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$2.0M | -$2.5M | -$7.7M | -$7.2M | -$14.3M | -$11.4M | -$7.8M | -$8.2M | -$12.5M |
| EPS | $-5.24 | $-6.62 | $-20.99 | $-14.56 | $-16.03 | $-9.50 | $-2.30 | $-1.28 | $-0.90 |
| EPS (Diluted) | $-5.24 | $-6.62 | $-20.99 | $-14.56 | $-16.03 | $-9.50 | $-2.30 | $-1.28 | $-0.90 |
| Shares Outstanding (Diluted) | $384482 | $376982 | $366583 | $494513 | $893203 | $1.2M | $3.4M | $6.4M | $13.8M |
Price
| Price | $0.80 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ASBP · BCTX · CRIS · DARE · ENTO · FBLG · LEXX
Explore sector: Healthcare · Biotechnology
More sections of HOTH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks